hodgkin lymphoma
In Advanced Hodgkin Lymphoma, New 6-Drug Regimen Exceeds Standard for Efficacy, Tolerability
A phase 3 randomized trial has shown that compared with BEACOPP, a standard seven-drug regimen for classic advanced ...
JUNE 26, 2024
Nivolumab Substituted for Brentuximab Vedotin in Hodgkin Therapy Improves Outcomes
In older patients with advanced-stage classic Hodgkin lymphoma (cHL), outcomes are particularly improved with lower ...
FEBRUARY 21, 2024
My Experience as a Surgical Resident With Cancer
Whenever my attendings would ask me about my journey with cancer, one of the most common questions I was asked was ...
JUNE 16, 2023
ECHELON-1: BV + Chemo New First-Line Standard for Advanced cHL
Brentuximab vedotin combined with AVD chemotherapy is the first regimen to demonstrate improved OS versus ...
DECEMBER 7, 2022
Adcetris Gets New Indication
The FDA approved brentuximab vedotin (Adcetris, Seagen) for the treatment of pediatric patients aged 2 years and ...
NOVEMBER 16, 2022
Adult Cancer Survivors Linked to Higher Cardiovascular Disease Risk
A new study confirms what many adult survivors of cancer have long known: Cancer treatment can cure the disease but ...
SEPTEMBER 16, 2022
Brentuximab Vedotin Improves Overall Survival in Stage III, IV Hodgkin Lymphoma
A new study has confirmed the superiority of brentuximab vedotin (Adcetris, Seagen) plus doxorubicin, vinblastine ...
SEPTEMBER 7, 2022
BV + Bendamustine May Be Effective for Primary Refractory HL
The combination of brentuximab vedotin and bendamustine may be effective in inducing complete remission in patients ...
JUNE 13, 2017
Baseline Fatigue Determines Long-Term Fatigue in HL
In a patient with Hodgkin lymphoma the severity of long-term fatigue is associated primarily with fatigue levels at ...
NOVEMBER 7, 2016
When Brentuximab Fails Hodgkin Lymphoma Patients, Pembrolizumab May Be Effective
In early-stage research, 65% of Hodgkin lymphoma patients with refractory or relapsed disease after brentuximab ...
NOVEMBER 6, 2016
Stem Cell Transplants Safe for Elders With Relapsed/Refractory Hodgkin Lymphoma
Patients with Hodgkin lymphoma should not be excluded as candidates for autologous hematopoietic cell ...
OCTOBER 24, 2016
Fatigue Persists Well After Successful HL Treatment
Persistent fatigue is common among survivors of Hodgkin lymphoma (HL) and does not depend on the intensity of ...
SEPTEMBER 28, 2016